Treatment of Hodgkin's disease: A twenty-year follow-up of patients at a center in Korea

Yonsei Medical Journal

Volumn 47, Issue 4, 2006, Pages 455-465

  Cheong, June Won ^a   Park, Soo Young ^a   Roh, Jae Kyung ^a   Suh, Chang Ok ^a   Hahn, Jee Sook ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Hodgkin's disease; Korea; Twenty year survival

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; AMENORRHEA; AZOOSPERMIA; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INCIDENCE; KOREA; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

EID: 33748325786     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.4.455     Document Type: Review

References (27)

1. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
2. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9:21-35.
3. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-49.
4. Hahn JS, Ko YW, Min YH, Kim NK, Kim DJ, Kim MC, et al. Statistical analysis of malignant lymphoma in Korea. Korean J Hematol 1995;30:197-214.
5. Diehl V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann Hematol 1993:66:139-40.
6. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
7. Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 2000; 11 (Suppl 1):81-5.
8. Kim HT, Im YH, Suh CI, Park YS, Kang WK, Heo DS, et al. Malignant lymphoma in Korea. J Korean Cancer Assoc 1992;24:92-101.
9. Kim KW, Chang YB, Kim MC, Son CH. Clinical observation on 55cases of Hodgkin's disease. Korean J Hematol 1982;17:35-44.
10. Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma-survival and prognostic factors. Yonsei Med J 1997;38:270-84.
11. Park JB, Seo CW, Kim SH, Lee KN, Song HH, Park SS, et al. Conventional Treatment in Patients with Hodgkin's Disease. J Korean Cancer Assoc 1999;31:821-9.
12. Ryoo BY, Kim HG, Kim TY, IM YH, Lee JO, Kang TW, et al. C-MOPP/ABV hybrid chemotherapy for previously untreated, advanced Hodgkin's disease. Korean J Hematol 1998;33:54-64.
13. Ahn JS, Lee KS, Lee JT, Im SA, Heo DS, Bang YJ, et al. COPP/ABV hybrid chemotherapy in patients with Hodgkin's disease. J Korean Cancer Res Assoc 1998;30: 818-26.
14. Longo DL, Duffey PL, DeVita VT Jr, Wiernik PH, Hubbard SM, Phares JC, et al. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991;9:1409-20.
15. Jung KH, Shin DB, Kim HA, Park YI, Kim TY, Park KC, et al. Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, prednisone (C-MOPP) in Hodgkin's disease. J Korean Cancer Assoc 1991;23: 806-13.
16. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-306.
17. Morgenfeld MC, Pavlovsky A, Suarez A, Somoza N, Pavlovsky S, Palau M, et al. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. Cancer 1975;36:1241-9.
18. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 1975;36: 252-9.
19. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986;104:739-46.
20. Bonadonna G, Santoro A, Bonfante V, Valagussa P. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. Cancer Treat Rep 1992;66: 881-7.
21. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998;16:19-26.
22. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients-report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998-1006.
23. Connors JM. State-of-the-art Therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-8.
24. Kreuser ED, Felsenberg D, Behles C, Seibt-Jung H, Mielearek M, Diehl V, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3 Suppl 4;105-10.
25. Levis A, Vitolo U, Ciocca Vasino MA, Cametti G, Urgesi A, Bertini M, et al. Predictive, value of the early response to chemothevapy in high-risk stages II and III Hodgkin's disease. Cancer 1987;60:1713-9.
26. Gospodarowicz MK, Sutcliffe SB, Clark RM, Dembo AJ, Fitzpatrick PJ, Munro AJ, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiant Oncol Biol Phys 1992;22:859-65.
27. Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991;114:361-5.